Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
6.01
+0.42 (7.51%)
At close: May 12, 2025, 4:00 PM
6.00
-0.01 (-0.17%)
After-hours: May 12, 2025, 7:58 PM EDT
Altimmune Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Altimmune stock have an average target of 21, with a low estimate of 12 and a high estimate of 26. The average target predicts an increase of 249.42% from the current stock price of 6.01.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 3, 2025.
Analyst Ratings
The average analyst rating for Altimmune stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +99.67% | Apr 3, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $25 | Buy | Reiterates | $25 | +315.97% | Apr 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +99.67% | Mar 18, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $25 | Buy | Reiterates | $25 | +315.97% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +99.67% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
n/a
from 20.00K
Revenue Next Year
n/a
EPS This Year
-1.48
from -1.34
EPS Next Year
-1.75
from -1.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 135.1M | ||
| Avg | n/a | n/a | 39.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.30 | -1.30 | -0.65 | ||
| Avg | -1.48 | -1.75 | -1.33 | ||
| Low | -1.66 | -2.26 | -2.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.